TABLE 4.
Adverse Events Reported in 4% or More of Patients in Any Subgroup During the Double-blind Treatment Period in ASCEND-PD
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.